Fontaine et al. Em se tratando de estabilizadores de humor, fatores adicionais podem estar envolvidos. A molindona associou-se a discreta perda de peso -0,81 kg. Outros estudos apresentaram achados semelhantes.
|Published (Last):||20 February 2008|
|PDF File Size:||20.53 Mb|
|ePub File Size:||4.55 Mb|
|Price:||Free* [*Free Regsitration Required]|
Brazilian Consensus on second-generation antipsychotics and metabolic disorders. OBJECTIVE: To discuss current aspects of use of antipsychotics considering their metabolic side effects profile, which includes weight gain, dyslipidemias, diabetes and metabolic syndrome. Such metabolic effects increase the risk of mortality by cardiovascular disease, which is the leading cause of death among schizophrenic patients.
METHOD: A consensus meeting was held, with participation of endocrinologists and psychiatrists specialists in schizophrenia and, based on a literature review, an article was elaborated emphasizing practical and helpful recommendations to clinicians. Efficacy and tolerability should be carefully balanced in all phases of treatment. Os psiquiatras participantes eram todos especialistas em psicoses e esquizofrenia.
Declarou ter recebido apoio direto ou indireto para pesquisa das seguintes companhias: Pfizer, Eli-Lilly, Acadia Pharmaceuticals e Janssen-Cilag. Fez palestras para a Astra-Zeneca e Eli-Lilly. Walter J. Parte 1: Tratamento agudo e Parte 2: Tratamento de longo prazo. Rev Psiq Clin. J Clin Psychiatry. American Psychiatric Association. Practice guideline for the treatment of patient with schizophrenia. Am J Psychiatry. International Pharmacological Algorithm Project.
Available at: www. Chou JC-Y. Prim Psychiatry. The Texas implementation of medication algorithms: update to the algorithms for treatment of bipolar I disorder. Prev Chronic Dis [serial online] Apr [date cited].
Consensus development conference on antipsychotic drugs and obesity Consensus Statement. Diabetes Care. Agency for Healthcare Research and Quality. Systems to rate the strength of scientific evidence. AHRQ publication no. World Health Organization. Preventing chronic diseases - a vital investment.
Obesity newsletter. Guidelines for healthy weight. N Engl J Med. Arq Bras Cardiol. Regional adiposity and morbidity. Physiol Rev. The metabolic syndrome and year risk of incident cardiovascular disease in the atherosclerosis risk in communities study. Emerging epidemic of type 2 diabetes in youth. Diabetes Care ;22 2 A new definition of the metabolic syndrome predicts incident coronary heart disease and stroke [abstract]. The metabolic syndrome and total and cardiovascular disease mortality in middle-aged men.
The metabolic syndrome as a predictor of type 2 diabetes. Association of the metabolic syndrome with history of myocardial infarction and stroke in the Third National Health and Nutrition Examination Survey. The impact of the metabolic syndrome and diabetes on mortality from coronary heart disease, cardiovascular disease and all causes in United States adults. Prevalence of the metabolic syndrome and its relation to all cause and cardiovascular mortality in non-diabetic European men and women.
Arch Int Med. Cardiovascular morbidity and mortality associated with the metabolic syndrome. Geneva, World Health Organization, Economics costs of diabetes in U. Wirshing D. Schizophrenia and obesity: impact of antipsychotic medications. Rev Psiquiatr Rio Gd Sul. Physical consequences of schizophrenia and its treatment: the metabolic syndrome.
Life Sci. Mortality in a cohort of patients with schizophrenia: a record linkage study. Can J Psychiatry.
Causes of the excess mortality of Schizophrenia. Brit J Psychiatry. Newcomer JW. Metabolic disturbances associated with antipsychotic use. Antipsychotic-induced weight gain: a comprehensive research synthesis. The distribution of body mass index among individuals with and without schizophrenia.
Antipsychotic-induced weight gain and metabolic abnormalities: implications for increased mortality in patients with schizophrenia. Metabolic considerations in the use of antipsychotic medications: a review of recent evidence. Baptista T. Body weight gain induced by antipsychotic drug: mechanisms and management. Acta Psychiatr Scand. Increased dyslipidemia in schizophrenic outpatients using new generation antipsychotics. Rev Bras Psiquiatr.
Clozapine: diabetes mellitus, weight gain, and lipid abnormalities: a five-year naturalistic study. Clinical guidelines on the identification, evaluation, and treatment of overweight and obesity in adults: the evidence report.
Obes Res. The metabolic syndrome in patients with severe mental illnesses. Atypical antipsychotics and metabolic dysregulation. J Clin Psychopharmacol. Metabolic syndrome in patients with schizophrenia. The prevalence of the metabolic syndrome in patients with schizoaffective disorder - bipolar subtype. Bipolar Disord. Characterizing coronary heart disease risk in chronic schizophrenia: high prevalence of the metabolic syndrome.
Prevalence of metabolic syndrome in hispanic and non-hispanic patients with schizophrenia. Meyer JM. Schizophrenia and the metabolic syndrome. Serious cardiovascular events and mortality among patients with schizophrenia. J Nerv Ment Dis. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. Schizophr Res. The prevalence of metabolic syndrome among schizophrenia patients is double that of the general population.
The Metabolic Syndrome is an independent predictor of cardiovascular disease in Type 2 diabetic subjects. Prospective data from the Verona Diabetes Complications Study. Diabet Med. Guedes EP. In: Godoy-Matos AF, organizador. Mancini MC.
In: Lyra R, Cavalcanti N, organizador. Diabetes Mellitus. Rio de Janeiro: Diagraphic Editora; A double-blind, placebo-controlled trial of sibutramine forn olanzapine-associated weight gain. A double-blind, placebo-controlled trial of sibutramine for clozapine-associated weight gain. Taflinski T, Chojnacka J. Sibutramine-associated psychotic episode. Dietary Guidelines revision
Abuso de antipsicóticos en hogares de ancianos
Si un medicamento le causaba insomnio y ansiedad, le daban otro distinto para contrarrestar esos efectos secundarios. En lugar de ello, la medicaron para convertirla en una persona sumisa. A ello se suma el hecho de que los CNA reciben un salario muy bajo, por lo que muchos de ellos deben trabajar largas horas. Los CMS, que supervisan los hogares de ancianos que reciben subsidios de programas federales, declaran que han estado trabajando para corregir las deficiencias detectadas en estas instituciones, incluido el uso inapropiado de medicamentos. Para Kathi Levine y su madre, estos remiendos llegan muy tarde.
Todo lo que deberías saber sobre los antipsicóticos